A. G. Maiche

Skin Protection by Sucralfate Cream During Electron Beam Therapy

Acute skin reactions, such as erythema and moist desquamation, constitute major problems during radiotherapy of superficially located tumours. There are no drugs available for the skin care. Sucralfate, a widely used anti-ulcer drug, has anti-inflammatory properties, and it activates cell proliferation. Based on these data and our previous experience of sucralfate cream on the aging skin we performed a double-blind randomized study to compare the efficacy of sucralfate cream to a base cream in 50 breast cancer patients receiving postoperative electron beam therapy to their chest wall. The acute radiation reaction of the skin was statistically significantly prevented by the sucralfate cream. The recovery of the skin was also significantly faster in the sucralfate cream group. Side-effects due to the cream were rare.

Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients

59 patients who had earlier developed an infection following antineoplastic chemotherapy were randomised to receive either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF+quinolone as prophylaxis during subsequent identical chemotherapy courses. 30 patients received 48 courses of G+CSF, while 29 patients received 44 courses of G-CSF+ofloxacin or ciprofloxacin. The overall infection rate was 23%. Patients with WHO grade IV leukopenia at the onset of prophylactic treatment developed infection in 61% of cases when on G-CSF, but only in 22% when on G-CSF+quinolone (P = 0.002). Patients with initial leukopenia of grade WHO III-I had only a 11% infection rate showing no significant difference between the treatment groups. The median duration of leukopenia < 1 x 10(9)/l was 4 days for patients receiving G-CSF alone and 3.5 days for those receiving additional quinolone. Patients developing infection had grade IV leukopenia for a median of 5 days. Both prophylactic treatments were well tolerated. We conclude that when prophylactic G-CSF is initiated at WHO grade IV leukopenia, addition of an oral quinolone reduces the risk of infection.

Oral tegafur in the treatment of metastatic breast cancer: A phase II study

Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg. Of these, 21 were evaluable for response. The overall response rate was 29%; six (two in lungs, two in skin and two in lymph nodes) of 44 evaluable lesions (14%) responded to therapy. Haematological toxicity was mild, and no other dose-limiting toxicity was seen. The data indicate some activity in heavily pretreated metastatic breast cancer even after previous 5-FU therapy.

Risk of Cervical Cancer Among Wives of Men with Carcinoma of the Penis

The relationship between carcinomas of the penis and cervix uteri was analyzed in married couples. The final series comprised 239 patients with squamous cell carcinoma of the penis and their 224 wives. Two wives were found to have squamous cell carcinoma of the cervix uteri. The expected number of cervical cancers within the group of wives was 1.88, the relative risk thus being 1.05 (95% confidence interval 0.13-3.8). The incidence of condylomas has increased during the recent decades, while that of carcinomas of the penis and uterine cervix has decreased. The results of this study did not support the hypothesis that wives of men with penile cancer incur an increased risk of carcinoma of the cervix uteri. Although there is much evidence from a large number of studies that human papilloma virus (HPV) has a role in the aetiology of cervical cancer, our study suggests that HPV associated with genital malignancies has a low infectivity or that these cancers have multifactorial aetiology.

Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer

Spontaneous regression of advanced breast cancer is a rare phenomenon. Efforts have been made in order to explain it by means of immunological mechanisms. Corticosteroids have demonstrated important efficacy in the treatment of breast cancer. We present a patient with stage IV breast cancer in whom large tumour masses dramatically regressed during treatment with dexamethasone alone. In this patient, histological and hormonal findings, with results of analyses on surface and intracellular blood cells markers demonstrated significant redistribution of lymphocytes and accumulation of natural killer cells in tumour masses. It seems that dexamethasone has acted through the hypophyse against cancer.

Renal cell carcinoma in a natural remaining kidney after two kidney transplantations. Case report.

A 57-year-old woman with nephropathy following a streptococcal infection had received a kidney transplant in 1980 and 1986 and immunosuppressive treatment since 1980. Renal cell carcinoma was found in the right native kidney in 1991, with skeletal metastases. Nephrectomy was performed and radiotherapy given. Removal of non-functioning kidneys would prevent development of such cancer.

Transfer factor immunotherapy in Hodgkin's and non-Hodgkin's lymphoma

SummaryHuman dialyzable transfer factor was administered in a double-blind fashion to patients with Hodgkins disease and non-Hodgkins lymphoma. Two groups were examined; patients with active disease and patients in remission. Parameters of cellular and humoral immunity were studied. The effect of transfer factor on the clinical condition was not evaluated.Transfer factor tended to intensify the skin test reactions of patients in remission to several recall antigens, but had no effect on the other parameters or the other patient group.